Two things happened in biology recently that belong in a computing notebook rather than a life sciences one.
At CASP13 in December, DeepMind's AlphaFold took first place in free modelling, the category for proteins with no useful template. By the assessors' summed z-scores it finished a clear first, and it predicted roughly 24 of 43 hard targets to high accuracy where the next best managed about 14. CASP has run since 1994 and improvement is normally incremental. This was not incremental.
The method is the interesting part. It predicts a distribution over distances between residue pairs with a deep network, turns that into a potential and then optimises the structure by gradient descent. No new physics, no new chemistry. A representation problem, solved with the same machinery that was doing image classification four years ago.
Meanwhile a nanopore sequencer weighs about 100 grams, draws power over USB and produces gigabytes of sequence from a device you can carry in a coat pocket. Read lengths run to megabases. Accuracy is worse than the big short-read platforms and improving steadily.
Why this is a computing story¶
Because the bottleneck moved.
The hard part of structural biology used to be the instrument: a crystallography beamline, a cryo-EM microscope, the better part of a year per structure. Those were capital assets with queues attached. The hard part now is partly a model, and a model is a file.
The same inversion is happening at the other end. Sequencing used to mean a room. It now means a dongle and a laptop, and the limiting factor is the basecaller, which is a neural network converting raw ionic current into bases. The instrument is commodity and the intelligence is software.
That is a shape this notebook has seen before. It is the same move as software-defined networking and, before that, as the general-purpose CPU displacing fixed-function silicon. When the clever part migrates from the device into code, the device gets cheap and the code becomes the thing worth owning.
What it costs¶
Confidence, mostly, and in a field where the failure mode is expensive.
A predicted structure is a hypothesis with a plausible shape, carrying none of the authority of an experimental observation. The distinction will blur the moment predictions are good enough to be convenient. CASP reports confidence estimates; the literature that cites a predicted structure three papers downstream will not. Expect a decade of results resting on predictions nobody re-derived, and expect a few of them to be wrong in ways that take years to surface.
The second cost is that the training data is the product of the slow experimental work being displaced. The PDB is a public good built over decades by people doing crystallography. A model trained on it, released as a black box, consumes that commons and does not replenish it. If structure prediction reduces the incentive to deposit new experimental structures, the next generation of models has less to learn from.
What it makes possible¶
Start with the work that simply could not be afforded before.
A neglected disease has no structural biology programme because no one will fund a decade of beamline time for a parasite that infects people who cannot pay. If predicting a target's structure costs compute rather than capital, that calculation changes, and the bottleneck moves to the much cheaper question of who is willing to do the chemistry. The same applies to antimicrobial resistance, where the economics have been broken for thirty years.
Then the pocket sequencer, which is the part this lab finds most interesting. A device that runs on a laptop in a field station means identifying an outbreak where it happens rather than shipping samples to a reference lab in another country and waiting. During an epidemic the latency between "someone is ill" and "we know what this is" is the whole game. Portable sequencing collapses it from weeks to a day, and it does so without requiring that the affected country own a genomics institute.
Further out, the combination is what matters. Cheap sequencing produces variants; cheap structure prediction says what a variant does to a protein. That loop, run continuously rather than per-project, is a surveillance system for biology itself. We would expect it to be how the next pandemic is characterised, assuming anybody has built the plumbing by then.
Who ends up owning the fold¶
The uncomfortable arithmetic. The experimental data is public and the models trained on it need not be.
AlphaFold's results were published; the weights are another question, and the pattern across machine learning is that the paper arrives and the artefact does not. If the definitive structure-prediction model is a service, then structural biology acquires an API key, and a field that ran on shared data for thirty years starts running on a terms-of-service agreement. Query limits are a research agenda. So is pricing.
The sequencer has a different chokepoint and a sharper one. The hardware is cheap but the basecaller is proprietary and the flow cells are consumables sold by one company. A device whose consumables have a single supplier is a subscription with a plastic case. Open basecallers exist and lag. That gap is the whole question.
And the data is human. A sequence is the most identifying record a person has: it implicates relatives who never consented, and it cannot be rotated after a breach. Population-scale sequencing is being assembled right now, mostly by national programmes with mostly good intentions, and the governance is downstream of the engineering rather than ahead of it. A genomic database amounts to a permanent register of people and their descendants.
Here at AxisOps our position on this is the same as everywhere else: prefer the instrument you can own, run the model yourself where a model exists to be run and treat a biological dataset as the most sensitive thing in the building, because it is. The compute is the easy part.
What would change our mind¶
If predicted structures turn out to be reliable enough that experimental validation becomes optional, the commons argument above gets much weaker and this reads as alarmism. We do not think that happens soon, but we would rather be wrong about it than right.